Neuland Laboratories Limited has reported a strong fiscal performance for the year ended March 31, 2026, featuring a consolidated revenue of ₹2,02,298.54 lakhs and a net profit of ₹36,399.84 lakhs. The Board of Directors has recommended a final dividend of ₹34/- per share. Additionally, the company is embarking on a ₹143.4 crore capacity enhancement project at its Unit 1 facility to meet the increasing demand from customers.
Financial Performance Overview
For the financial year 2025-26, Neuland Laboratories achieved significant growth in its financial metrics. The company reported a total consolidated revenue of ₹2,02,298.54 lakhs, compared to ₹1,47,683.73 lakhs in the previous year. The net profit for the year stood at ₹36,399.84 lakhs, showcasing robust operational performance. These audited results have been approved by the Board of Directors with an unmodified audit opinion.
Dividend Recommendation
Reflecting its strong financial health and commitment to shareholder value, the Board has recommended a final dividend of ₹34/- (340%) per equity share for the financial year 2025-26. This dividend is subject to the approval of shareholders at the upcoming 42nd Annual General Meeting, which is scheduled for August 4, 2026. The record date for determining eligible shareholders for this dividend has been set for July 24, 2026.
Strategic Capacity Expansion
To address the growing demand for its products, the company has approved an investment of ₹143.4 crores to enhance production capacity at its Unit 1 facility located at Bonthapally Village, Telangana. The project aims to add 120.5 KL of capacity to the existing 256 KL base. This expansion is expected to be completed within a timeframe of 12 to 18 months and will be funded through a combination of internal accruals and borrowings.
Board Appointments
The company also announced the appointment of Dr. Mauricio Futran as an Additional Director, categorized as Non-Executive Non-Independent, effective May 12, 2026. Dr. Futran brings over 40 years of experience in chemical engineering and process development from his tenure at global pharmaceutical leaders, which is expected to provide valuable strategic insights to the Board.
Source: BSE
